Your browser doesn't support javascript.
loading
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Borghaei, H; de Marinis, F; Dumoulin, D; Reynolds, C; Theelen, W S M E; Percent, I; Gutierrez Calderon, V; Johnson, M L; Madroszyk-Flandin, A; Garon, E B; He, K; Planchard, D; Reck, M; Popat, S; Herbst, R S; Leal, T A; Shazer, R L; Yan, X; Harrigan, R; Peters, S.
Afiliação
  • Borghaei H; Hematology and Oncology Department, Fox Chase Cancer Center, Philadelphia, USA. Electronic address: Hossein.Borghaei@fccc.edu.
  • de Marinis F; Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Dumoulin D; Department of Pulmonary Medicine, Erasmus Medisch Centrum, Rotterdam, the Netherlands.
  • Reynolds C; Ocala Cancer Center, Florida Cancer Specialists and Research Institute - North Region (SCRI), Ocala, USA.
  • Theelen WSME; Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Percent I; North Port Cancer Center, Florida Cancer Specialists and Research Institute - South Region (SCRI), Port Charlotte, USA.
  • Gutierrez Calderon V; Department of Medical Oncology, Hospital Regional Universitario de Málaga, Málaga, Spain.
  • Johnson ML; Department of Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, USA.
  • Madroszyk-Flandin A; Department of Medicine, Institut Paoli-Calmettes, Marseille, France.
  • Garon EB; Division of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles.
  • He K; Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, USA.
  • Planchard D; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
  • Reck M; Department of Thoracic Oncology, LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
  • Popat S; Lung Unit, Department of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.
  • Herbst RS; Section of Medical Oncology, Yale University, New Haven.
  • Leal TA; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta.
  • Shazer RL; Department of Clinical Research and Development, Mirati Therapeutics, Inc., San Diego, USA.
  • Yan X; Department of Clinical Research and Development, Mirati Therapeutics, Inc., San Diego, USA.
  • Harrigan R; Department of Clinical Research and Development, Mirati Therapeutics, Inc., San Diego, USA.
  • Peters S; Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Ann Oncol ; 35(1): 66-76, 2024 Jan.
Article em En | MEDLINE | ID: mdl-37866811
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piridinas / Carcinoma Pulmonar de Células não Pequenas / Anilidas / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piridinas / Carcinoma Pulmonar de Células não Pequenas / Anilidas / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article